Research Centre

Research Centre Overview

Over the years, Beacon Hospital has established itself as a reputable cancer specialist hospital in Malaysia, renowned for pioneering Cyberknife radiosurgery treatment in the South-east Asian region, while offering other forms of cancer treatments, such as radiotherapy, chemotherapy, immunotherapy and targeted therapy. At Beacon Hospital, our oncologists practise evidence-based care and prescribe the most effective treatment tailored to suit each patient’s disease condition.

In response to the demand of evidence-based clinical research, our oncology team actively participates in, and contributes to, international clinical trials and research studies with the aim of developing better oncology treatments for the patients. Our clinical research activities commenced in 2008 and is currently ongoing as we adhere to our belief that our participation in clinical trials will provide the most updated knowledge in treatment therapies and exclusive access to recent, more advanced breakthrough treatments.

While research studies are of importance in therapeutic advancement, we seek to ensure that the rights, safety and well-being of patients involved in clinical trials are of utmost priority. Apart from the fact that all our clinical studies have secured approval from the Medical and Research Ethics Committee of the Ministry of Health, Malaysia, we also comply with local and international Good Clinical Practice (GCP) standards to safeguard the ethical interests of trial patients.

For those who are interested and wanted to know more about these ongoing trials, please do not hesitate to contact us at +603 7620 7979 ext 2854 or you could drop us an email at

To date, our oncology team has participated in numerous clinical trials:

NoClinical TrialStatus
1A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy In Treatment Naive Subjects With PD-L1 Positive Advanced Or Metastatic Non-Small Cell Lung Cancer (Keynote 042)Active
2A Phase Ib/II Multicenter, Randomized, Open Label Trial To Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy As Second-line Treatment In Subjects with MET Positive, Locally Advanced Or Metastatic Nonsmall Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance To Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) TherapyActive
3A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma PatientsActive
4Studies On Epigenetic Changes In Nasopharyngeal CancerActive
5Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer CareActive
6Healthcare Performance Measurement And Reporting For Breast Cancer Services In MalaysiaCompleted
7A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction AdenocarcinomaCompleted
8A Randomized, 3 Arm, Multicentre, Phase III Study To Evaluate The Efficacy And The Safety Of T-DM1 Combined With Pertuzumab Or T-DM1 Combined With Pertuzumab-Placebo (Blinded For Pertuzumab), Versus The Combination Of Trastuzumab Plus Taxane, As First Line Treatment In HER2- Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer (MBC)Completed
9A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.Completed
10An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)Completed

Apart from oncology clinical trials, our consultants from other centres of excellence have also made substantial contributions to their clinical specialty with their published research. Below are the research publications (abstract, research papers, poster presentations, etc) produced by our consultants:

NoPublication TitleName of ConsultantType of Presentation
1Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical PhotographsDr Ong Chin TuanPoster
Find Consultant